<?xml version="1.0" encoding="UTF-8"?>
<p>Proteasome inhibition with bort has immunomodulatory properties relevant to allogeneic HSCT, as previously highlighted. Based on encouraging phase I/II results in HLA-mismatched T-replete RIC HSCT, we undertook a prospective randomized evaluation of aGvHD prophylaxis with conventional tac/mtx (arm A) 
 <italic>vs</italic>. two novel regimens of short-course bort for transplantation recipients lacking 8/8 HLA-matched related donors: bort plus tac/mtx (arm B), and bort plus sir/tac (arm C).
</p>
